R&G PharmaStudies Co. Ltd. A (301333) - Cash Flow Conversion Efficiency

Latest as of June 2022: 0.090x

Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has a cash flow conversion efficiency ratio of 0.090x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.98 Million ≈ $6.00 Million USD) by net assets (CN¥454.13 Million ≈ $66.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is R&G PharmaStudies Co. Ltd. A's balance sheet to measure how much of total assets are equity-financed.

R&G PharmaStudies Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2019–2025)

This chart illustrates how R&G PharmaStudies Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is R&G PharmaStudies Co. Ltd. A's earnings quality to evaluate the quality of earnings relative to operating cash generation.

R&G PharmaStudies Co. Ltd. A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
PWR Holdings Ltd AU:PWH	0.100x
Jilin Liyuan Precision Manufacturing Co Ltd SHE:002501	-0.165x
Vgi Partners Global Investments Ltd AU:VG1	0.143x
MorningStar Partners, L.P. NYSE:TXO	0.040x
Media and Games Invest PLC XETRA:M8G	0.001x
Yijiahe Technology Co Ltd SHG:603666	-0.030x
Anel Elektrik Proje Taahhut ve Ticaret AS IS:ANELE	-0.029x
Queclink Wireless Solutions Co Ltd SHE:300590	0.043x

Annual Cash Flow Conversion Efficiency for R&G PharmaStudies Co. Ltd. A (2019–2025)

The table below shows the annual cash flow conversion efficiency of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of R&G PharmaStudies Co. Ltd. A.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥1.98 Billion ≈ $289.11 Million	CN¥114.20 Million ≈ $16.71 Million	0.058x	-31.42%
2024-12-31	CN¥1.84 Billion ≈ $268.68 Million	CN¥154.76 Million ≈ $22.65 Million	0.084x	-23.20%
2023-12-31	CN¥1.75 Billion ≈ $256.76 Million	CN¥192.56 Million ≈ $28.18 Million	0.110x	+34.06%
2022-12-31	CN¥1.59 Billion ≈ $233.21 Million	CN¥130.47 Million ≈ $19.09 Million	0.082x	-68.72%
2021-12-31	CN¥437.81 Million ≈ $64.07 Million	CN¥114.57 Million ≈ $16.77 Million	0.262x	+99.97%
2020-12-31	CN¥336.98 Million ≈ $49.31 Million	CN¥44.10 Million ≈ $6.45 Million	0.131x	-68.41%
2019-12-31	CN¥249.74 Million ≈ $36.55 Million	CN¥103.48 Million ≈ $15.14 Million	0.414x	--

About R&G PharmaStudies Co. Ltd. A

SHE:301333 China Biotechnology

Market Cap

$716.54 Million

CN¥4.90 Billion CNY

Market Cap Rank

#10343 Global

#2731 in China

Share Price

CN¥50.70

Change (1 day)

+7.14%

52-Week Range

CN¥44.50 - CN¥91.20

All Time High

CN¥91.20